• Home
  • Lavipharm
  • Nitrong, Trinipatch, Nitrosylon, Triniplas, Keritrina

Nitrong, Trinipatch, Nitrosylon, Triniplas, Keritrina

Nitrong, Trinipatch, Nitrosylon, Triniplas, Keritrina
Product Description

A latest generation nitroglycerin patch for the treatment of coronary artery disease and heart failure. Transdermal Drug Delivery Systems (TDDS) are one of the pharmaceutical technologies, in which Lavipharm is actively and successfully engaged. TDDSs are placed on the skin and allow specific drug substances to penetrate into the bloodstream through the layers of the skin. This controlled delivery has many benefits compared to other forms, but most importantly, it offers safety and a better quality of life to the patient.

Read more Show less

Lavipharm

  • Country/Region:
    Greece
  • Founded:
    1911
  • On CPHI since:
    2019
  • Certificates:
    1
  • Employees:
    250 - 499
Company types
Distributor/Import Export
Manufacturer/Innovator
Wholesale/Retail
Primary activities
Finished Formulation products Distributor/Buyer
OTC
Out-licensing specialist
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile
Categories
more categories Show less
Specifications
  • Details
    It is a translucent thin and elegant patch,in three strengths, delivering 5mg, 10mg and 15mg of nitroglycerin per day, respectively. Indicated for the prevention of angina pectoris in patients with coronary artery disease.
  • Selling Points
    Cardiovascular Health; International Approvals/Standards; Packaging; Reputation;
  • Transdermal delivery system for continuous 24-hour release
  • Available in multiple strengths: 5mg, 10mg, and 15mg per day
  • Thin, translucent, and discreet patch design
  • Approved and marketed internationally under various brand names
  • Proven efficacy in angina prevention for patients with coronary artery disease

  • Model
    Transdermal patch – Nitroglycerin
  • Supplied from
    Greece
  • Measured In
    piece
    • More specifications Fewer specifications
    Sales Markets
    Show more Show less

    Lavipharm

    • Country/Region:
      Greece
    • Founded:
      1911
    • On CPHI since:
      2019
    • Certificates:
      1
    • Employees:
      250 - 499
    Company types
    Distributor/Import Export
    Manufacturer/Innovator
    Wholesale/Retail
    Primary activities
    Finished Formulation products Distributor/Buyer
    OTC
    Out-licensing specialist
    Pharmaceutical Company (generic finished products)
    Pharmaceutical Company (innovator finished products)
    View company profile

    More Products from Lavipharm (1)

    • Fentadur, Dolfen, Durfenta, Opiodur, Fentapon, Lafene

      Product Fentadur, Dolfen, Durfenta, Opiodur, Fentapon, Lafene

      A fentanyl transdermal delivery system, developed by Lavipharm's research laboratories in the USA  is a small, thin and easy to adhere patch for the management of chronic pain. It is designed to deliver the analgesic substance fentanyl safely and effectively through the skin. This three-day pa...